Impact of COVID mRNA administration on studied population

This presentation explores the integration of SARS-CoV-2 mRNA vaccines and immune checkpoint inhibitors (ICIs) for cancer treatment. It highlights key findings such as enhanced Type I IFN responses and clinical improvements, supported by preclinical studies showing increased immune activation and PD-L1 modulation. Mechanisms like RNA nanoparticle-induced MDA5 sensing and reprogramming immunity are discussed. Clinical observations confirm elevated immune biomarkers and activation trends,...